{
    "nct_id": "NCT03524612",
    "official_title": "A Phase II, Open-label, Prospective, Single-arm, Study to Assess Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP Who Are Refractory or Relapsed After First-line Steroids",
    "inclusion_criteria": "1. Signed informed consent must be obtained prior to participation in the study\n2. Patients ≥ 18 years old\n3. Patients with a confirmed diagnosis of primary ITP, who are not responsive or in relapse after a first line of steroid therapy ± intravenous immunoglobulin (IVIG) (used as a rescue therapy)\n4. Platelet count < 30×10^9/L and assessed as needing treatment (per physician's discretion\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "1. ITP patients previously treated with any ITP second-line therapies, thrombopoietin receptor (TPO-R) agonists for ITP, except steroids / IVIG\n2. Patients who relapsed more than one year after the end of first-line full course of steroid therapy\n3. Patients with a diagnosis of secondary thrombocytopenia\n4. Patients who have life threatening bleeding complications per investigator discretion\n5. Patients who had a deep vein thrombosis or arterial thrombosis in the 6 months preceding enrollment\n6. Serum creatinine ≥ 1.5 mg/dL\n7. Total bilirubin > 1.5 × upper limit of normal (ULN)\n8. Aspartate transaminase (AST) > 3.0 × ULN\n9. Alanine transaminase (ALT) > 3.0 × ULN\n10. Patients who are human immune deficiency virus (HIV), hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg) positive\n11. Patients with hepatic impairment (Child-Pugh score > 5)\n12. Patients who have active malignancy\n13. Patients with any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with subject's safety, obtaining informed consent or compliance with the study procedures per investigator discretion\n14. History or current diagnosis of cardiac disease indicating significant risk of safety for Patients participating in the study\n15. Patients with known active or uncontrolled infections not responding to appropriate therapy\n16. Patients with evidence of current alcohol/drug abuse\n17. Women of child-bearing potential and sexually active males unwilling to use adequate contraception during the study\n18. Female Patients who are nursing or pregnant (positive serum or urine B-human chorionic gonadotrophin (B-hCG) pregnancy test) at screening or pre-dose on Day 1\n\nOther protocol-defined inclusion/exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}